EUVIMEDEUVIMED entdecken
Open Access

AAV-Vectored Expression of Marburg Virus–Neutralizing Antibody MR191 Provides Complete Protection From Challenge in a Guinea Pig Model

Amira D Rghei, Wenguang Cao, Shihua He, Jordyn A Lopes, Nicole Zielinska, Yanlong Pei, Brad Thompson, Logan Banadyga iD, Sarah K Wootton

The Journal of Infectious Diseases · 2023

DOI: 10.1093/infdis/jiad345 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2023. Verfasst von Amira D Rghei und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathobiology, University of Guelph, Guelph, Ontario, Canada. Hauptthemen laut MEDLINE: Marburgvirus, Marburg Virus Disease. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CIHR, Public Health Agency of Canada, Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although there are no approved countermeasures available to prevent or treat disease caused by Marburg virus (MARV), potently neutralizing monoclonal antibodies (mAbs) derived from B cells of human survivors have been identified. One such mAb, MR191, has been shown to provide complete protection against MARV in nonhuman primates. We previously demonstrated that prophylactic administration of an adeno-associated virus (AAV) expressing MR191 protected mice from MARV. Here, we modified the AAV-MR191 coding sequence to enhance efficacy and reevaluated protection in a guinea pig model. Remarkably, 4 different variants of AAV-MR191 provided complete protection against MARV, despite administration 90 days prior to challenge. Based on superior expression kinetics, AAV-MR191-io2, was selected for evaluation in a dose-reduction experiment. The highest dose provided 100% protection, while a lower dose provided ∼88% protection. These data confirm the efficacy of AAV-mediated expression of MR191 and support the further development of this promising MARV countermeasure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MarburgvirusMarburg Virus DiseaseHumansGuinea PigsAnimalsMiceB-LymphocytesAntibodies, Neutralizing

Stichwörter der Autor:innen

Marburg virusadeno-associated virus (AAV) vectorfilovirusgene therapyguinea pig challenge modelmonoclonal antibodyvectored immunoprophylaxiszoonotic pathogen

Substanzen

Antibodies, Neutralizing

Autor:innen und Institutionen

  • Department of Pathobiology, University of Guelph, Guelph, Ontario, Canada.
  • Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
  • Avamab Pharma, Inc, Calgary, Alberta, Canada.
  • Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Manitoba, Canada.

ORCID-Profile: Logan Banadyga

Förderung

  • CIHR
  • Public Health Agency of Canada
  • Canadian Institutes of Health Research

Zitieren

APA

Rghei, A. D., Cao, W., He, S., Lopes, J. A., Zielinska, N., Pei, Y., Thompson, B., Banadyga, L., & Wootton, S. K. (2023). AAV-Vectored Expression of Marburg Virus–Neutralizing Antibody MR191 Provides Complete Protection From Challenge in a Guinea Pig Model. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiad345

Vancouver

Rghei AD, Cao W, He S, Lopes JA, Zielinska N, Pei Y, et al. AAV-Vectored Expression of Marburg Virus–Neutralizing Antibody MR191 Provides Complete Protection From Challenge in a Guinea Pig Model. The Journal of Infectious Diseases. 2023. doi:10.1093/infdis/jiad345

BibTeX
@article{Rghei2023,
  author = {Rghei, Amira D and Cao, Wenguang and He, Shihua and Lopes, Jordyn A and Zielinska, Nicole and Pei, Yanlong and Thompson, Brad and Banadyga, Logan and Wootton, Sarah K},
  title = {AAV-Vectored Expression of Marburg Virus–Neutralizing Antibody MR191 Provides Complete Protection From Challenge in a Guinea Pig Model},
  journal = {The Journal of Infectious Diseases},
  year = {2023},
  doi = {10.1093/infdis/jiad345}
}
Kostenlos starten →